ZyCov-D vaccine by Zydus Cadila had recently got the nod for human clinical trials (AFP). More than 140 candidate vaccines to cure COVID-19 infection, are under various stages of development. Indian manufacturers account for 60% of vaccine supplies made to UNICEF, said government. The approval for human trials for two made-in-India COVID-19 vaccines marks the 'beginning of the end,' the government said today.
Two COVID-19 vaccine candidates — Covaxin, developed by the Hyderabad-based Bharat Biotech International Limited in collaboration with the ICMR and the National Institute of Virology (NIV) and ZyCov-D vaccine by Zydus Cadila — had recently got the nod for human clinical trials from the Drug Controller General of India. Both have been approved for Phase II, III trials. Citing India's role in global efforts to develop the vaccine, the ministry said, "In the past years, India has emerged as one of the significant vaccine manufacturing hubs. Indian manufacturers account for 60% of vaccine supplies made to UNICEF." "The vaccine for novel coronavirus may be developed anywhere in the world, but without Indian manufacturers involved the production of required quantity is not going to be feasible," it added. After medical experts had cautioned against rushing a COVID-19 vaccine, the ICMR on Saturday said, "The aim is to complete these phases at the earliest, so that population-based trials for efficacy could be initiated without delay."
A dozen institutes have been selected for clinical trials of the indigenous COVID-19 vaccine (BBV152 COVID vaccine), the government's top medical research body has said.
Read More Latest Bollywood Movie Reviews & News
Read More Sports News, Cricket News
Read More Latest Mobile, Laptop News & Review